摘要
背景技术DNA拓扑异构酶II-α(Top2-α)是复制,转录,重组和染色质重塑中DNA的管理的必需酶,是最重要的抗癌靶标之一。许多分子被设计为Top2-α抑制剂。然而,一些研究已经显示Top2中的多态性和突变赋予了大多数这些抗癌药物的抗性。这项研究的目的是计算检查Top2-α基因组变异可能影响其对阿姆斯克和米托蒽醌作为酶的重要抑制剂的机制。 结果:结果表明,变异体K529E,R568H,R568G和T530M可能影响Atsacrine的Top2-α抑制作用,导致可能的耐药性。此外,R487K和Y481C变体可以改变酶对米托蒽醌的反应。 结论:这些结果可以促进Top2-α变体更有效的药物的预测和开发,使癌症化疗更有效果
关键词: 癌症治疗,耐药性,拓扑异构酶II,拓扑异构酶抑制剂,非同义多态性,对接。
Current Cancer Drug Targets
Title:Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An In Silico Approach
Volume: 17 Issue: 7
关键词: 癌症治疗,耐药性,拓扑异构酶II,拓扑异构酶抑制剂,非同义多态性,对接。
摘要: Background: DNA topoisomerase II-α (Top2-α), an essential enzyme for the management of DNA during replication, transcription, recombination, and chromatin remodeling, is one of the most important anticancer targets. Numerous molecules have been designed as Top2-α inhibitors. However, several studies have shown that polymorphisms and mutations in Top2 have conferred resistance to most of these anticancer drugs. The aim of this study was to computationally examine the mechanisms by which genomic variations in Top2-α could affect its resistance to Amsacrine and Mitoxantrone as important inhibitors of the enzyme.
Results: The results showed that variants K529E, R568H, R568G and T530M could affect Top2-α inhibition by Amsacrine causing possible drug-resistant. Moreover, R487K, and Y481C variants could change the response of the enzyme to Mitoxantrone. Conclusion: These results could facilitate the prediction and development of more effective drugs for Top2-α variants, making the cancer chemotherapy more effectivExport Options
About this article
Cite this article as:
Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An In Silico Approach, Current Cancer Drug Targets 2017; 17 (7) . https://dx.doi.org/10.2174/1568009617666161109142629
DOI https://dx.doi.org/10.2174/1568009617666161109142629 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics Recent Developments of Phototherapy Based on Graphene Family Nanomaterials
Current Medicinal Chemistry Kinase Inhibitors with Redox and Anti-inflammatory Activities
Current Topics in Medicinal Chemistry Vascularization of Biomaterials for Bone Tissue Engineering: Current Approaches and Major Challenges
Current Angiogenesis (Discontinued) Bioactive Metabolites from Pathogenic and Endophytic Fungi of Forest Trees
Current Medicinal Chemistry Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management
Current Pharmaceutical Design Ganglioside GM3 and Its Role in Cancer
Current Medicinal Chemistry Current Research on Opioid Receptor Function
Current Drug Targets Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Regulation of Microtubule: Current Concepts and Relevance to Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets Research Progress on the Antitumor Effects of Rhein: Literature Review
Anti-Cancer Agents in Medicinal Chemistry Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs
Current Cancer Therapy Reviews The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Letters in Drug Design & Discovery Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design